CureVac

Boehringer Ingelheim, CureVac collaborate on lung cancer immunotherapy

Thursday, September 18, 2014 01:39 PM

Boehringer Ingelheim and CureVac, a clinical stage biopharmaceutical company based in Tubingen, Germany, have announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer.

More... »


CureVac, Sanofi Pasteur ink agreement to develop mRNA-based prophylactic vaccine

Thursday, July 3, 2014 10:00 AM

CureVac, a German-based clinical-stage biopharmaceutical company, has inked an agreement with Sanofi Pasteur, the vaccines division of Sanofi, to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen.

More... »


CureVac collaborates with Cancer Research Institute, Ludwig Cancer Research

Monday, November 4, 2013 01:41 PM

The nonprofit Cancer Research Institute (CRI), Ludwig Cancer Research and CureVac, a clinical stage biopharmaceutical company that has developed a new class of therapies and vaccines based on messenger RNA (mRNA), will collaborate to enable clinical testing of novel cancer immunotherapy treatment options.

More... »

CureVac secures $104M in Series D financing

Wednesday, September 19, 2012 12:04 PM

CureVac, a German clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, today announced the completion of a $140 million financing round with its main investor, dievini Hopp BioTech Holding.

More... »

CureVac, Sanofi Pasteur collaborate in $33 million research project

Tuesday, November 15, 2011 11:20 AM

CureVac has signed several agreements with Sanofi Pasteur, the vaccines division of Sanofi. Under these agreements, CureVac and Sanofi Pasteur will further develop and apply CureVac’s proprietary RNActive technology platform to the development of vaccines against several infectious diseases.

More... »


CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs